Immuneering Corporation Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Immuneering Corporation (IMRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.36% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-05
- Immuneering Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-03-31 was 4.14%, a 9.01% decline year-over-year.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-03-31 was 4.55%, a 5.60% decline year-over-year.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-03-31 was 4.82%, a 23.91% increase year-over-year.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-03-31 was 3.89%, a 59.43% increase year-over-year.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.55%, a 5.60% decline from fiscal 2024.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.82%, a 0.42% increase from fiscal 2023.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.80%, a 15.66% increase from fiscal 2022.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.15%, a 142.69% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.36% 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | 4.14% 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | 4.55% 10-K · filed 2026-03-06 | |||
| 2025-09-30 | 4.55% 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | 4.55% 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | 4.55% 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | 4.82% 10-K · filed 2026-03-06 | |||
| 2024-09-30 | 4.82% 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | 4.82% 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | 4.82% 10-Q · filed 2025-05-05 | |||
| 2023-12-31 | 4.80% 10-K · filed 2025-03-20 | |||
| 2023-09-30 | 4.24% 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | 4.07% 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | 3.89% 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | 4.15% 10-K · filed 2024-03-01 | |||
| 2022-09-30 | 3.31% 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 3.31% 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | 2.44% 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | 1.71% 10-K · filed 2023-03-06 | |||
| 2021-09-30 | 1.71% 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | 1.71% 10-Q · filed 2022-08-10 | |||
| 2021-03-31 | 1.71% 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | 1.45% 10-K · filed 2022-03-10 | |||
| 2020-09-30 | 1.21% 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |